- Company
- 3 generics for Champix have been withdrawn in just one year
- by Lee, Tak-Sun Jul 28, 2021 05:54am
- Varenicline, a smoking cessation drug, is being withdrawn. It is believed that the impurity incident, which occurred last month, affected the cancer. According to the MFDS on the 26th, eight items of Varenicline have been withdrawn since June. On the 22nd of last month, the MFDS also began a safety survey after recovering Pfizer's Champ
- Policy
- The weighted average price may vary when charging Xarelto
- by Lee, Hye-Kyung Jul 28, 2021 05:54am
- When pharmacies claim Bayer Korea's Xarelto, they need to reconfirm the purchase price. This is because the weighted average price may change due to changes in drug prices due to lawsuits such as suspension of the execution of notification on drug price cuts. In particular, if a pharmacy claims a drug price change without checking it, it n
- Policy
- Moderna vaccine by Samsung Biologics is supplied worldwide
- by Kim, Jung-Ju Jul 27, 2021 05:36am
- Prime Minister Kim Bu-gyeom briefly mentioned in a radio media interview today (the 26th) when Samsung Biologics' moderna COVID vaccine will be released, and quarantine authorities said that hundreds of millions of doses of Samsung Biologics products will be supplied to the world except the U.S. next year. The KDCA made the announcement in
- Policy
- When will Phase 3 trials of K-COVID-19 vaccines begin?
- by Lee, Tak-Sun Jul 27, 2021 05:35am
- Development of domestic COVID-19 vaccines has come to a standstill before entering the final stages - the phase 3 trials. Cellid, which had shown the fastest progress in development, is planning to reenter phase 1 trials with an improved version of its vaccine. Due to such changes, the industry has a negative outlook on the commercialization of
- Company
- 19% of valsartan Rxs disappear 3 years after impurity issue
- by An, Kyung-Jin Jul 27, 2021 05:35am
- Three years have passed since the valsartan impurity issue swept across the pharmaceutical industry, however, the valsartan market is still showing no signs of recovery. Prescriptions of products containing valsartan as monotherapy and combination therapy both decreased by nearly 20%. Analysts believe that distrust in valsartan after the imp
- Company
- Sales in the SGLT-2 diabetes drug market rose by 10%
- by Kim, Jin-Gu Jul 27, 2021 05:35am
- Prescription performance of compound drugs has increased significantly in the market for diabetic drugs in the SGLT-2 inhibitors. Outpatient Rx increased by 23% in the second quarter of the year. The single formulation only increased by 4% during the same period, showing slowing down. According to UBIST, a pharmaceutical market research
- Company
- Ultomiris can be prescribed in general hospitals
- by Eo, Yun-Ho Jul 26, 2021 05:51am
- According to related industries, Ultomiris (Ravulizumab), a treatment drug for paroxysmal nocturnal hemoglobinuria (PNH) supplied by Alexion to the domestic market, recently passed the D.C. of Seoul National University Hospital. It will be quickly prescribed after obtaining approval from the MFDS in May last year and being listed on the in
- Policy
- Onivyde listed at ₩672,320 as RSA refund type
- by Kim, Jung-Ju Jul 26, 2021 05:50am
- Servier Korea’s 'Onivyde injection(irinotecan liposome),’ which is used in second-line or higher treatment of pancreatic cancer, will be available with insurance benefits at &8361;672,320 per vial starting next month. The Ministry of Health and Welfare announced today(23rd) that the Health Insurance Policy Deliberative Committee delibe
- Policy
- New PBAC members to make big reimbursmeent decisions in 2H
- by Lee, Hye-Kyung Jul 26, 2021 05:50am
- From September, new members of the Drug Reimbursement Evaluation Committee (DREC) of the Health Insurance Review and Assessment Service will be conducting evaluations on the adequacy of pharmaceutical reimbursements. PBAC members that will start committee activity from the second half of this year, will carry out major deliberations and tasks
- Opinion
- [Reporter's view] The MFDS shouldn't selectively explain
- by Lee, Tak-Sun Jul 26, 2021 05:50am
- In a recent series of incidents, the MFDS did not properly explain, causing confusion. It wasn't a big issue, but it's not something to skip. The issue of whether the RNA-based QTP104, which was approved for phase 1 clinical trial on the 20th, was initially marked as "domestic development" on a site where approval status can be checked, bu
